Pharma exports to US to be high this year

Pharmaceutical Exports Promotion Council's DG says US FDA's actions resulted in exports dropping to around 26 %

Pharmaceutical exports, which has seen a drop on a series of actions by the USFDA in the last fiscal, is expected to recover this year.

Exports to the US, last year, saw a drop due to a series of actions against the Indian drug manufacturers, including Ranbaxy.

While the export of Indian medicines last year to the US constituted around 26 per cent of the total exports, this is expected to touch 35 per cent this year, said PV Appaji, director general of Pharmaceutical Exports Promotion Council of India (Pharmexcil).

“If every thing goes well, we expect exports to the US to constitute around 35 per cent of total exports. Over a period of time, almost 30 per cent of our exports were catered to the US market, but last year, with several issues related to the USFDA’s action against Indian companies, this has come down to around 26 per cent,” he said.